Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Has Average Price Target of $38.50 According to Brokerages

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $38.50.

ALGS has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating on shares of Aligos Therapeutics in a research report on Monday, August 10th. Weiss Ratings cut Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. Finally, Jefferies Financial Group started coverage on Aligos Therapeutics in a research note on Monday. They issued a “strong-buy” rating for the company.

Hedge Funds Weigh In On Aligos Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Rockefeller Capital Management L.P. lifted its holdings in shares of Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after acquiring an additional 9,000 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Aligos Therapeutics by 17.6% during the first quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after acquiring an additional 15,006 shares in the last quarter. SummitTX Capital L.P. lifted its position in Aligos Therapeutics by 6.7% in the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after acquiring an additional 9,375 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in Aligos Therapeutics by 1,652.8% during the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock worth $1,707,000 after acquiring an additional 216,646 shares during the last quarter. 60.43% of the stock is owned by institutional investors.

Aligos Therapeutics Stock Down 34.9%

Shares of ALGS opened at $2.57 on Friday. The company has a 50 day moving average of $5.18 and a 200-day moving average of $6.12. Aligos Therapeutics has a twelve month low of $2.56 and a twelve month high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last announced its earnings results on Friday, November 6th. The company reported ($2.09) EPS for the quarter, topping the consensus estimate of ($2.28) by $0.19. The business had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $4.85 million. Aligos Therapeutics had a negative net margin of 197.01% and a negative return on equity of 206.30%. On average, sell-side analysts predict that Aligos Therapeutics will post -6.86 EPS for the current fiscal year.

About Aligos Therapeutics

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections. Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH.